TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12190808
Drug: Interscalene brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene brachial plexus block (ISB) with 15 ml of ropivacaine (5 mg/ml)
Study: 12190808
Drug: Subacromial bursa
Normalized name: Capsella bursa-pastoris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial bursa block (SUB) with 15 ml of ropivacaine (5 mg/ml)
Study: 12190808
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) with 15 ml of 0.9% saline
Study: 2534373
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of ipratropium bromide (IPB) followed by 5 mg of salbutamol sulfate (SAS)
Study: 2534373
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of salbutamol sulfate (SAS)
Study: 2534373
Drug: Sequential inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential inhaled SAS after IPB
Study: 2534373
Drug: Repeated dose
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dose of SAS
Study: 2534373
Drug: Double-dose SAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose SAS
Study: 21720704
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + low-dose IL-2 (CT+IL-2)
Study: 19695392
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg oral dose on day 1)
Study: 1550909
Drug: Sublingual tablets
Normalized name: Fentanyl Sublingual Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablets
Study: 1550909
Drug: Oral sustained-release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained-release tablets
Study: 1550909
Drug: Sustained-release tablets
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tablets
Study: 29745307
Drug: Dance program,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance program, twice a week for 10 weeks
Study: 27865961
Drug: Lifetime major
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifetime major depressive disorder (L-MDD)
Study: 27865961
Drug: Lifetime generalized
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifetime generalized anxiety disorder (L-GAD)
Study: 15866630
Drug: Daclizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (1 mg/kg in two doses; preoperatively and on day 14) combined with steroids, mycophenolate mofetil (initial dose of 2 g/d), and tacrolimus (0.1 mg/kg per day).
Study: 12063522
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (empty liposomes)
Study: 9457941
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (Crinone 8%) administered twice daily from day 14, containing 90 mg of micronized progesterone.
Study: 9457941
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) progesterone, 100 mg administered from cycle days 15 to 27.
Study: 2234874
Drug: Ibuprofen (26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (26 patients)
Study: 2234874
Drug: Paracetamol/codeine/caffeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/codeine/caffeine combination (Solpadeine) (25 patients)
Study: 376074
Drug: Ovarian irradiation
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian irradiation (2000 rads in 5 days) plus prednisone, 7.5 mg daily
Study: 29873278
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavior therapy (iCBT) for chronic tinnitus
Study: 23160488
Drug: omega‐6 once
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega‐6 once daily
Study: 21736785
Drug: Decaffeinated green
Normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated green tea extract (DGT; 530 mg containing about 400 mg total catechins/capsule, twice daily)
Study: 11244517
Drug: Adjunct balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct balloon angioplasty
Study: 9189106
Drug: Teicoplanin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (12 mg/kg intravenously)
Study: 30624344
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo or alternative treatment during the crossover)
Study: 28951525
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g mixed eicosapentaenoic acid/docosahexaenoic acid in soft-gel capsules
Study: 28951525
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g mixed eicosapentaenoic acid/docosahexaenoic acid in Smartfish drinks
Study: 28951525
Drug: Both omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both omega-3 PUFA formulations
Study: 26068234
Drug: High-dose Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Vitamin D3 supplementation
Study: 19650808
Drug: Regional anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional anticoagulation (heparin pre-filter plus post-filter protamine) plus antiaggregation (pre-filter prostacyclin) [Group 1 (G1)]
Study: 19650808
Drug: Systemic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic heparin anticoagulation without antiaggregation [Group 2 (G2)]
Study: 10357429
Drug: 0.12% aspartame
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% aspartame solution
Study: 10357429
Drug: 24% polycose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% polycose solution
Study: 31074660
Drug: Self-Management program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Management program plus Physical Therapy
Study: 31074660
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (standard medical treatment)
Study: 31842940
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (methotrexate, hydroxychloroquine, and sulfasalazine)
Study: 29046405
Drug: Total potato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total potato consumption in PREDIMED (81.9 ± 40.6 g/d)
Study: 29046405
Drug: Total potato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total potato consumption in SUN (52.7 ± 33.6 g/d)
Study: 19092350
Drug: Intravenous hypocaloric
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hypocaloric nutrition starting 20 hours before the operation
Study: 21823168
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of olanzapine (OLZ)
Study: 9580762
Drug: High-iron formula
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-iron formula (12.7 mg/L of elemental iron)
Study: 9580762
Drug: Low-iron formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-iron formula (2.3 mg/L of elemental iron)
Study: 8206405
Drug: Groshong catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groshong catheter for intraperitoneal therapy
Study: 12357164
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia (n = 16)
Study: 29685179
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral doxycycline (400 mg) and metronidazole (400 mg)
Study: 26661344
Drug: Patient-performed daily
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-performed daily spirometry and positive expiratory pressure (PEP)
Study: 25109873
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole with antidepressant
Study: 21119408
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (820 nm, 3 J/cm2, 300-mW output power), applied 2 times per week for a total of 10 sessions.
Study: 16169561
Drug: IFN beta‐1a,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN beta‐1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif)
Study: 16169561
Drug: IFN beta‐1a,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN beta‐1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex)
Study: 11755292
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (4 IU subcutaneously every other day for three months)
Study: 11720604
Drug: Candesartan 32
Normalized name: candesartan 32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 32 mg once daily
Study: 8546999
Drug: Oral liarozole
Normalized name: letrozole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liarozole at a daily dose of 75 mg b.i.d. for 12 weeks, with possible increase to 150 mg b.i.d. after 1 month if no improvement
Study: 8546999
Drug: Oral liarozole
Normalized name: letrozole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liarozole
Study: 381957
Drug: Ticrynafen (250‐‐500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticrynafen (250‐‐500 mg/day)
Study: 381957
Drug: Hydrochlorothiazide (50‐‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50‐‐100 mg/day)
Study: 27470470
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (10.5 therapist visits, 38.6 minutes of arm therapy, 16 repetitions of functional tasks per visit)
Study: 26177655
Drug: JNJ-42847922 (3-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42847922 (3-30 mg/kg)
Study: 14581115
Drug: Naloxone (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.01 mg/kg)
Study: 11061771
Drug: Cisapride (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (0.2 mg/kg/dose 3 times/day)
Study: 6512867
Drug: Standard Couple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Couple Therapy
Study: 6512867
Drug: Group Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Therapy
Study: 24844747
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oral tiagabine
Study: 22825365
Drug: Larazotide acetate
Normalized name: Larazotide
DrugBank: Larazotide (DB05645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larazotide acetate (0.25, 1, 4, or 8 mg)
Study: 20116087
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg) and acetyl salicylic acid (100 mg) after coronary stenting for myocardial infarction
Study: 18050208
Drug: Methotrexate ≤20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate ≤20 mg weekly
Study: 16181235
Drug: LGH (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGH (0.10 mg/day)
Study: 16181235
Drug: SGH (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGH (mean dose 0.48 mg/day)
Study: 30476335
Drug: Intervention tools
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention tools (e.g., prompts and standing desks)
Study: 24456128
Drug: Biologically equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologically equivalent dose (BED) Gy3 ≥ 80 Gy
Study: 23016867
Drug: Metronidazole (MTZ)
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole (MTZ) 400 mg thrice a day (TID) for 14 days
Study: 23016867
Drug: Metronidazole +
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole + Amoxicillin (MTZ+AMX) 500 mg TID for 14 days
Study: 23016867
Drug: Chlorhexidine 0.12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine 0.12% rinsed twice a day (BID) for 2 months
Study: 11481402
Drug: Touchi-extract (TE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Touchi-extract (TE) 0.3 g before each meal for 3 months
Study: 9951916
Drug: Desferrioxamine infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine infused at a dose of 80 mg/kg per cycle
Study: 2561147
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg once a day)
Study: 1841828
Drug: Phenobarbital (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (20 mg/kg loading dose)
Study: 594674
Drug: Preoperative irradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative irradiation (total dose of 3,300 rads in 3 weeks)
Study: 24010675
Drug: LY2196044 (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2196044 (125 or 250 mg/d)
Study: 20941459
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg bid, 10 mg bid or 20 mg qd)
Study: 18583436
Drug: n‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA supplements
Study: 12170445
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m(2) plus cisplatin 75 mg/m(2) every 3 weeks
Study: 11441409
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m(2) plus carboplatin to an area under the curve of 6 mg/mL x min every 3 weeks
Study: 11441409
Drug: vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinorelbine 25 mg/m(2) weekly plus cisplatin 100 mg/m(2) monthly
Study: 9608923
Drug: Hemisynthesis diosmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemisynthesis diosmine 600 mg, one tablet per day taken in the morning
Study: 9608923
Drug: Usual tablet
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual tablet formulation of diosmine 300 mg taken twice a day (morning and evening)
Study: 8001524
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg retinol as retinyl palmitate every 4 months for 1 year
Study: 2648213
Drug: Acyclovir, 800
Normalized name: Acyclovir, 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 800 mg 5 times daily for 7 days
Study: 20217150
Drug: Gabapentin 200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 200 mg and imipramine 10 mg every 12 h orally (G400-I group)
Study: 20217150
Drug: Gabapentin 200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 200 mg every 12 h orally (G400 group)
Study: 20217150
Drug: Gabapentin 400
Normalized name: gabapentin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 400 mg every 12 h orally (G800 group)
Study: 20217150
Drug: Imipramine 10
Normalized name: trimipramine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 10 mg every 12 h orally (I group)
Study: 9589244
Drug: NPL insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPL insulin
Study: 16048153
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard injection without Vibraject)
Study: 2006119
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intramuscular polyestradiol phosphate (PEP) and oral ethinyl estradiol
Study: 2006119
Drug: Intramuscular PEP
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular PEP alone
Study: 6332893
Drug: Co-trimoxazole (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (twice daily for 6 months)
Study: 31859575
Drug: Biological mesh
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological mesh (Veritas®)
Study: 31859575
Drug: Both biological
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both biological and synthetic meshes
Study: 22137185
Drug: SPARX computerized
Normalized name: tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPARX computerized Cognitive Behavioural Therapy (cCBT) completed over 5 weeks (n=20)
Study: 19770739
Drug: Intra-aortic balloon
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-aortic balloon pump (IABP) therapy
Study: 19770739
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (without IABP)
Study: 12042265
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone orally followed by 800 microg vaginal misoprostol
Study: 7570567
Drug: Amrinone (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (bolus 1 mg/kg, continuous infusion of 5‐10 micrograms/kg/min)
Study: 2160667
Drug: Intensive combined
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive combined chemotherapy (B)
Study: 2160667
Drug: High-dose half-body
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose half-body irradiation (HBI) (A)
Study: 6448131
Drug: Topical 1
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1 percent clindamycin phosphate (Cleocin T)
Study: 6448131
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline 500 mg/day
Study: 23537750
Drug: Split-dose sodium
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose sodium picosulphate/magnesium oxide/anhydrous citric acid (Citrafleet(®)) regimen administered 2 to 6 hours before colonoscopy
Study: 23537750
Drug: Split-dose sodium
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose sodium picosulphate/magnesium oxide/anhydrous citric acid (Citrafleet(®)) regimen
Study: 19118083
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg twice daily for 9 days, coadministered with a single 5‐mg dose of fingolimod on the 4th day of ketoconazole treatment.
Study: 19118083
Drug: Fingolimod 5
Normalized name: fingolimod 500 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 5 mg single dose in period 1 without ketoconazole.
Study: 9599555
Drug: Cardioselective beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioselective beta 1 antagonists for more than three months
Study: 9599555
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (never received beta-blockers)
Study: 9599555
Drug: Cardioselective beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioselective beta 1 antagonists
Study: 9208342
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms cerivastatin as a 1-minute bolus infusion
Study: 9208342
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms cerivastatin orally as tablets
Study: 9208342
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms cerivastatin as an oral solution
Study: 7119508
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 96.6 and 135 million units of human interferon-alpha over 12-15 weeks
Study: 7119508
Drug: Intralesional injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injections of human interferon-alpha (double blind, placebo-controlled)
Study: 7119508
Drug: Intralesional injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injections of human interferon-alpha
Study: 29258890
Drug: Galantamine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (8 mg)
Study: 26085028
Drug: Insulin glargine/glulisine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin glargine/glulisine once daily
Study: 26085028
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart/aspart protamine 30/70 twice daily
Study: 19175979
Drug: Ziprasidone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (80 to 160 mg/day)
Study: 19175979
Drug: Risperidone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (6 to 10 mg/day)
Study: 17156266
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of D‐amphetamine + physiotherapy
Study: 17156266
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of L‐dopa + physiotherapy
Study: 17156266
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of D‐amphetamine + 50 mg of L‐dopa + physiotherapy
Study: 15669780
Drug: Mismanagement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mismanagement of insulin
Study: 15669780
Drug: Eating 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eating 3 meals a day, getting insulin every day, and more assistance with meals
Study: 12057081
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin re‐uptake inhibitors (SSRIs)
Study: 3542323
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg sustained‐release furosemide preparation (FR)
Study: 3542323
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg standard furosemide tablet (F)
Study: 29724115
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group from two archived randomized control trials (RCTs) assessing intentions, normative beliefs, values, and substance use.
Study: 27855660
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 mcg/kg (Group F)
Study: 27855660
Drug: Oxycodone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.2 mg/kg (Group O)
Study: 25164220
Drug: Sequential combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combination therapy (iloprost: 10 µg/inhalation, 6 times per day for 6 months, then add oral tadalafil (5 mg/d) till 12 months, n = 32)